Physician profile
Robert D Collins
NPI 1447250220
$3,762.37
in general payments reported to CMS, 2019-2025
24 companies · $75.49 in 2025
The $75.49 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $840 · 2021: $1,107 · 2022: $359 · 2023: $200 · 2025: $75.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.26 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,278.56 | 2019-2022 | |
| Amgen INC. | $553.55 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $490.88 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $452.12 | 2019-2022 | |
| Amarin Pharma, INC. | $191.10 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $184.72 | 2022-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.06 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $90.58 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.16 | 2019-2025 | Jardiance |
| Pfizer INC. | $45.66 | 2019-2020 | |
| Vital Connect, INC | $31.64 | 2022 | |
| Edwards Lifesciences Corporation | $29.25 | 2019 | |
| Medtronic Vascular, INC. | $26.75 | 2019-2020 | |
| Vivus LLC | $22.00 | 2019 | |
| Springworks Therapeutics, INC. | $19.91 | 2025 | Ogsiveo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.12 | 2025 | Ozempic |
| Lexicon Pharmaceuticals, INC. | $18.77 | 2023 | Inpefa |
| Biosense Webster, INC. | $18.73 | 2019 | |
| Abbott Laboratories | $17.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.39 | 2019 | |
| Merck Sharp & Dohme LLC | $16.04 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.14 | 2019 | |
| Amryt Pharma Holdings LTD | $13.31 | 2021 | |
| Alnylam Pharmaceuticals INC. | $13.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.